The Evaluation of Injection Site Pain and Adherence in Patients Switching from a Low to High Concentration Adalimumab (AVT-02) Across Multiple Indications
Latest Information Update: 26 Feb 2025
At a glance
- Drugs Adalimumab (Primary)
- Indications Injection site pain
- Focus Therapeutic Use
- Acronyms EASE PAIN
- Sponsors JAMP Pharma
Most Recent Events
- 20 Feb 2025 Planned End Date changed from 13 Nov 2024 to 13 May 2025.
- 20 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 27 Jun 2023 New trial record